Theory in the Pathophysiology of carcinogenesis

Theory in the Pathophysiology of Carcinogenesis

Volumn , Issue , 2011, Pages

  Agius, Lawrence M ^a  

^a UNIVERSITY OF MALTA MEDICAL SCHOOL   (Malta)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882713856     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.2174/97816080526601110101     Document Type: Book

References (148)

1. Yeh HC, Huang CF, Yang SF, Li CC, Chang LL, Lin HH, et al. Nuclear factor-kappaB activation predicts an unfavourable outcome in human upper urinary tract urothelial carcinoma BJU. Int. 2010 Oct; 106(8): 1223-9.
2. Martin FT, Dwyer RM, Kelly J, Khan S, Murphy JM, Curran E, et al. Potential role of mesenchymal stem cells (MSCS) in the breast tumor microenvironment; stimulation of epithelial to mesenchymal transition (EMT). Breast Cancer Res Treat 2010 Nov; 124(2): 317-26.
3. Chang MH, Lee J, Han J, Park YH, Ahn JS, Park K, et al. Prognostic role of insulin-like growth factor receptor-1 expression in small-cell lung cancer. APMIS 2009 Dec, 117(12): 861-9.
4. Schrader J, Deuster O, Rinn B, Schulz M, Kautz A, Dodel R, et al. Restoration of contact inhibition in human glioblastoma cell lines after MIF knockdown BMC. Cancer 2009 Dec28; 9: 464.
5. Wang S, Liu Z, Wang L, Zhang X NF-kappaB signaling pathway, inflammation and colorectal cancer. Cell Mol Immunol 2009 Oct; 6(5): 327-34.
6. Noteborn MH Proteins selectively killing tumor cells. Euro J Pharmacol 2009 Dec25; 625(1-3): 165-73.
7. Yoshida S, Furukawa N, Haruta S, Tanase Y, Kanayama S, Noguchi T, et al. Expression profiles of genes involved in poor prognosis of epithelial ovarian carcinoma: a review. Int J Gynecol Cancer 2009 Aug; 19(6): 992-7.
8. Nakamura J, Kitajima Y, Kai K, Mitsuno M, Ide T, Hashiguchi K, et al. Hypoxia-inducible factor-1 alpha expression predicts the response to 5-fluorouracil-based adjuvant chemotherapy in advanced gastric cancer. Oncol Rep 2009 Oct; 22(4): 693-9.
9. Takeno S, Yamashita SI, Takahashi Y, Ono K, Kamei M, Moroga T, et al. Survivin expression in esophagealsquamous cell carcinoma: its prognostic impact ans splice variant expression. Eur J Cardiothorac Surg 2010 Feb; 37(2): 440-445.
10. Kim MS, Lee J, Sidransky D DNA methylation markers in colorectal cancer. Cancer Metastasis Rev 2010 Mar; 29(1): 181-206.
11. Thepot A, Hautefeuille A, Cros MP, Abedi-Ardekani B, Petra A, Damour O, et al. Intra-epithelial p63-dependent expression of distinct components of cell adhesion complexes in normal esophageal mucosa and squamous cell carcinoma. Int J Cancer 2010 Nov 1; 127(9): 2051-62.
12. Hu H, Zhang Y, Zou M, Yang S, Liang XQ Expression of TRF1, TRF2, TIN2, TERT, Ku70 and BRCA1 proteins is associated with telomere shortening and may contribute to multistage carcinogenesis of gastric cancer. J Cancer Res Clin Oncol 2010 Sep; 136(9): 1407-14.
13. Abel TW, Clark C, Bierie B, Chytil A, Aakie M, Gorska A, et al. GFAP-Cre-mediated activation of oncogenic K-ras results in expansion of the subventricular zone and infiltrating glioma. Mol Cancer Res 2009 May; 7(5): 645-53.
14. Abou-Ghazal M, Yang DS, Qiao W, Reina-Ortiz C, Wei J, Kong LY, et al. The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT 3 expression in human gliomas. Clin Cancer Res 2008 Dec 15; 14(24): 8228-35.
15. Schleuska-Lange A, Knupfer H, Lange TJ, Kiess W, Knupfer M, Cell proliferation and migration in glioblastoma multiforme cell lines are influenced by insulin-like growth factor I in vitro. Anticancer Res 2008 Mar-Apr; 28(2A): 1055-60.
16. Holtkamp N, Afanasieva A, Elstner A, van Landeghem FK, Konneker M, Kuhn SA, et al. Brain slice invasion model reveals genes differentially regulated in glioma invasion. Biochem Biophys Res Commun 2005 Nov 4; 336(4): 1227-33.
17. Dell'Albani P, Stem cell markers in gliomas. Neurochem Res 2008 Dec; 33(12): 2407-15.
18. Jeon JY,An JH, Kim Su, Park HG, Lee MA, Migration of human neural stem cells toward an intracranial glioma. Exp Mol Med 2008 Feb29; 40(1): 84-91.
19. Kong DS, Kim MH, Park WY, Suh YL, Lee JI, Park K, et al. The progression of gliomas is associated with cancer stem cell phenotype. Oncol Rep 2008 Mar; 19(3): 639-43.
20. Mott RT, Twiner KC, Bigner DD, McLendon RE, Utility of EGFR and PTEN numerical aberrations in the evaluation of diffusely infiltrating astrocytomas. Laboratory Investigation. J Neurosurg 2008 Feb; 108(2): 330-5.
21. Michotte A, Neyns B, Chaskis C, Sadones J, In't Veld P, Neuropathological and molecular aspects of lowgrade and high-grade gliomas. Acta Neurol Belg 2004 Dec; 104(4): 148-53.
22. Galarneau H, Villeneuve J, Gowing G, Julien JP, Vallieres L, Increased glioma growth in mice depleted of macrophages. Cancer Res 2007 Sep 15; 67(18): 8874-81.
23. Knizetova P, Darling JL, Bartek J, Vascular endothelial growth factor in astroglioma stem cell biology and response to therapy. J Cell Mol Med 2008 Jan-Feb; 12(1): 111-25.
24. Yu JM, Jun ES, Jung JS, Suh SY, Han JY, Kun JY, et al. Role of Wnt5a in the proliferation of human glioblastoma cells. Cancer Lett 2007 Nov 18; 257(2): 172-81.
25. Liang Y, Bollen AW, Gupta N, CC chemokine receptor-2A is frequently overexpressed in glioblastoma. J Neurooncol 2008 Jan; 86(2): 153-63.
26. Dunn GP, Dunn IF, Curry WT, Focus on TILS: Prognostic significance of tumor infiltrating lymphocytes in human glioma. Cancer Immuno 2007 Aug 13; 7: 12.
27. Masson F, Calzascia T, Di Berardino-Besson W, de Tribolet N, Dietrich PY, Walker PR, Brain microenvironment promotes the final functional maturation of tumor-specific effector CD8+ T cells. J Immunol 2007 Jul 15; 179(2): 845-53.
28. Nakagawa J, Saio M, Tamakawa N, Suwa T, Frey AB, Nonaka K, et al. TNF expressed by tumor-associated macrophages, but not microglia, can eliminate glioma. Int J Oncol 2007 Apr; 30(4): 803-11.
29. Suzuki SO, McKenney RJ, Mawatari SY, Mizuguchi M, Mikami A, Iwaki T, et al. Expression patterns of LIS1, dynein and their interaction partners dynactin, Nud E, Nud EL and Nud C in human gliomas suggest roles in invasion and proliferation. Acta Neuropathol 2007 May; 113(5): 591-9.
30. Liu X, Chen N, Wang X, He Y, Chen X, Huang Y, et al. Apoptosis and proliferation markers in diffusely infiltrating astrocytomas: profiling of 17 molecules. J Neuropathol Exp Neurol 2006 Sep; 65(9): 905-13.
31. Lund CV, Nguyen MT, Owens GC, Pakchoiam AJ, Shaterian A, Kruse CA, et al. Reduced glioma infiltration in Src-deficient mice. J Neurooncol 2006 May; 78(1): 19-29.
32. Debinski W, Gibo DM, Fos-related antigen 1 modulates malignant features of glioma cells. Mol Cancer Res 2005 Apr; 3(4): 237-49.
33. Kaur B, Tan C, Brat DJ, Post DE, Van Meir EG, Genetic and hypoxic regulation of angiogenesis in gliomas. J Neurooncol 2004 Nov; 70(2): 229-43.
34. Svec J, Musilkova J, Bryndova J, Jirasek T, Mandys V, Kment M et al. Enhanced expression of proproliferative and antiapoptotic genes in ulcerative colitis-associated neoplasia. Inflamm Bowel Dis 010 Jul; 16(7): 1127-1137.
35. Carpentino JE, Hynes MJ, Appelman HD, Zheng T, Steindler DA, Scott EW et al. Aldehyde dehydrogenaseexpressing colon stem cells contribute to tumorigenesis in the transition from colitis to cancer. Cancer Res 2009 Oct15; 69(20): 8208-15.
36. Okayasu I, Yoshida T, Mikami T, Hana K, Yokozawa M, Araki K et al. Mucosal remodelling in long-standing ulcerative colitis with colorectal neoplasia; significant alterations of NCAM+ or alpha-SMA+ subepithelial myofibroblasts and interstitial cells. Pathol Int 2009 Oct; 59(10): 701-11.
37. Popivanova BK, Kostadinova FI, Furuichi K, Shamekh MM, Kondo T, Wada T et al. Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice. Cancer Res 2009, Oct1; 69(19): 7884-92.
38. Uronis JM, Muchlbauer M, Herfarth HH, Rubinas TC, Jones GS, Jobin C. Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS 2009 June24; 4(6): e6026.
39. Westbrook AM, Wei B, Breun J, Schiestl RH. Intestinal mucosal inflammation leads to systemic genotoxicity in mice. Cancer Res 2009 Jun1; 69(11): 4827-34.
40. Ohkusa T, Yoshida T, Sato N, Watanabe S, Tajiri H, Okayasu I. Commensal bacteria can enter colonic epithelial cells and induce proinflammatory cytokine secretion: a possible pathogenic mechanism of ulcerative colitis. J Med Microbiol 2009 May; 58(Pt5): 535-45.
41. Yang GY, Taboada S, Liao J. Inflammatory bowel disease: a model of chronic inflammation-induced cancer. Methods Mol Biol 2009; 511: 193-233.
42. Biasi F, Mascia C, Poli G. TGFbeta1 expression in colonic mucosa: modulation by dietary lipids. Genes Nutr 2007 Nov; 2(2): 233-43.
43. Seidelin JB, Nielsen OH. Attenuated apoptosis response to Fas-ligand in active ulcerative colitis. Inflamm Bowel Dis 2008 Dec; 14(12): 1623-9.
44. Garg M. Gain of antitumor functions and induction of differentiation in cancer stem cells contribute to complete cure and no relapse. crit Rev Oncog 2009; 15(1-2): 65-90
45. Du L, Pertsemlidis A. microRNAs and lung cancer: tumors and 22-mers. Cancer metastasis Rev 2010 Mar; 29(1): 109-22.
46. Saldana-Caboverde A, Kos L. Roles of endothelin signalling in melanocyte development and melanoma. Pigment cell melanoma Res 2010 Apr; 23(2): 160-70.
47. Sanci M, Dikis C, Inan S, Turkoz E, Dicle N, Ispahi C. Immunolocalization of VEGF, VEGF receptors, EGF-R and Ki-67 in leiomyoma, cellular leiomyoma and leiomyosarcoma. Acta Histochem 2011 May; 113(3): 317-25.
48. Kim SH, Richardson M, Chinnakannu K, Bai VU, Menon M, Barrack ER. Androgen receptor interacts with telomeric proteins in prostate cancer cells. J Biol chem. 2010 Apr 2; 285(14): 10472-6.
49. Radpour R, Barekati Z, Haghighi MM, Kohler C, Asadollah R, Torbati PM, et al.,. Correlation of telomere length shortening with promoter methylation profile of p16/Rb and p53/p21 pathways in breast cancer. Mod Pathol 2010 May; 23(5): 763-72.
50. Silva AG, Graves HA, Guffei A, Ricca T1, Mortara RA, Jasiulionis MG, et al. Telomere-centromere-driven genomic instability contributes to karyotype evolution in a mouse model of melanoma. Neoplasia 2010 Jan; 12(1): 11-9.
51. Resar LM. The high mobility group A1 gene: transforming inflammatory signals into cancer?. Cancer Res 2010 Jan15; 70(2): 436-9.
52. Wojewoda M, Duszynski J, Szezepanowska J . Antioxidant defence systems and generation of reactive oxygen species in osteosarcoma cells with defective mitochondria; effect of selenium. Biochem Biophys Acta 2010 Jun-Jul; 1797(6-7): 890-6.
53. Yu L, Guo WC, Zhao SH, Tang J, Chen JL . Mitotic arrest defective protein 2 expression abnormality and its clinicopathologic significance in human osteosarcoma. APMIS 2010 Mar; 118(3): 222-9.
54. Bakhshi J, Radhakrishnan V . Prognostic markers in osteosarcoma. Expert Rev Anticancer Ther 2010 Feb; 10(2): 271-87.
55. Rasola A, Sciacovelli M, Chiara F, Panti B, Brusilow WS, Bernardi P . Activation of mitochondrial ERK protects cancer cells from death through inhibition of the permeability transition. Proc Natl Acad Sci USA 2010 Jan12; 107(2): 726-31.
56. Abdou AG, Abd el-Wahed MM, Asaad NY, Samaka RM, Abdallaha R . Ephrin A4 expression in osteosarcoma, impact on prognosis and patient outcome. Indian J Cancer 2010 Jan-Mar; 47(1): 46-52.
57. Hirotsu M, Setoguchi T, Sasaki H, Matsunoshita Y, Gao H, Nagao H, et al. Smoothened as a new therapeutic target for human osteosarcoma. Mol Cancer 2010 Jan12; 9(1): 5.
58. Ryu K, Choy E, Yang C, Susa M, Hornicek FJ, Mankin H, et al. Activation of signal transducer and activator of transcription 3 (Stat 3) pathway in osteosarcoma cells and overexpression of phosphorylated-Stat 3 correlates with poor prognosis. J Orthop Res 2010 Jul; 28(7): 971-8.
59. Nathan SS, Huvor, Casas-Ganem JE, Yang R, Leukov I, Sowers R, et al. Tumor interstitial fluid pressure may regulate angiogenic factors in osteosarcoma. Ann Acad Med Singopore 2009 Dec; 38(12): 1041-7.
60. Halder C, Ossendorf C, Maran A, Yaszemski M, Bolander ME, Fuchs B, et al. Preferential expression of the secreted and membrane forms of tumor endothelial marker 7 transcripts in osteosarcoma. Anticancer Res 2009 Nov; 29(11): 4317-22.
61. Konopka G, Bonni A .Signaling pathways regulating gliomagenesis. Curr Mol Med 2003 Feb; 3(1): 73-84
62. Nozaki M, Tada M, Kobayashi H, Zhang CL, Sawamura Y, Abe H, et al.Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression. Neuro-Oncol 1999 Apr; 1(2): 124-37.
63. Kleihues P, Cavenee WK .Pathology and genetics: tumors of the nervous system. World Health Organization Classification of Tumors, 2nd Ed 9-29, IARC Lyon, France 2000.
64. Nozaki M, Tada M, Kobayashi H, Zhang CL, Sawamura Y, Abe H, et al.Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression. Neuro-Oncol 1999 Apr; 1(2): 124-37.
65. Fulci G, Ishii N, Maurici D, Gernart KM, Hainant P, Kaur B, et al.Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a pateitn with a 283H TP53 Germline mutation: Evidence for a precursor lesion. Cancer Res May 2002; 62: 2897-2905.
66. Ramaswamy S, Nakamura N, Sansal I, Bergeron L, Sallers WR .A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR. Cancer Cell 2002 Jul; 2(1): 81-91.
67. Holland EC, Hively WP, DePinho RA, Varmus HE .A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev 1998; 12: 3675-3685
68. Ruiz C, Huang W, Hegi ME, Lange K, Hanou MF, Fluri E, et al.Growth promoting signaling by tenascin-C. Cancer Res 2004 Oct 15; 64(20): 7377-85.
69. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, et al.A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 1994; 7727-7731.
70. Kamsasaran D, Qian B, Hawkins C, Stanford WL, Guha A .GATA6 is an astrocytoma tumor suppressor gene identified by gene trapping of mouse glioma model. Proc Natl Acad Sci USA 2007 May 8; 104(19): 8053-8.
71. Uhrbom L, Dai C, Celestino JC, Rosenblum MK, Fuller GN, Holland EC .Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt' Cancer Res 2002 Oct 1; 62(19): 5551-8.
72. Kirla RM, Haapasalo HK, Kalimo H, Salminen EK .Low expression of p27 indicates a poor prognosis in patients with high grade astrocytomas. Cancer 2003 Feb 1; 97(3): 644-8.
73. Benjamin R, Capparella J, Brown A .Classification of glioblastoma multiforme in adults by molecular genetics. Cancer J 2003 Mar-Apr; 9(2): 82-90.
74. Ramaswamy S, Nakamura N, Sansal I, Bergeron L, Sallers WR .A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR. Cancer Cell 2002 Jul; 2(1): 81-91.
75. Feldkamp M, Lau N, Rak J, Kerkel R, Guha A .Astrocytoma cell lines express high levels of vascular endothelial growth factor (VEGF) which is reduced by inhibition of the Ras signaling pathway. Int J Cancer 1999; 81: 118-124.
76. Broniscer A, Baker SJ, West AN, Fraser MM, Proko E, Kocak M, et al.Clinical and molecular characteristics of malignant transformation of low-grade glioma in children. J Clin Oncol 2007 Feb 20; 25(6): 682-9.
77. Wilhelmsson U, Eleasson C, Bjerkvig R, Pekny M .Loss of GFAP expression in high-grade astrocytomas does not contribute to tumor development or progression. Oncogene 2003 May 29; 22(22): 3407-11.
78. Mehrian-Shai R, Chen CD, Shi T, Horvath S, Nelson SF, Reichardt JK, et al.Insulin growth factor binding protein 2 is a candidate biomarker for PTEN status and P13K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci USA 2007 Mar 27; 104(13): 5563-8.
79. Shannon P, Sabla N, Lau N, Kamnesaran D, Gutmann DH, Guha A .Pathological and Molecular progression of Astrocytomas in a GFAP: 12V-Ha-Ras mouse astrocytoma model. Am J Pathol Sep 2005; 167: 859-867.
80. Broniscer A, Baker SJ, West AN, Fraser MM, Proko E, Kocak M, et al.Clinical and molecular characteristics of malignant transformation of low-grade glioma in children. J Clin Oncol 2007 Feb 20; 25(6): 682-9.
81. Fujisawa H, Kwerer M, Reis RM, Yonekawa Y, Kleihues P, Ohgaki H .Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter. Am J Pathol Aug 1999; 155: 387.
82. Ng SS, Cheung YT, An XM, Chen YC, Li M, Li GH, et al.Cell cycle-related kinase: a novel candidate oncogene in human glioblastoma. J Natl Cancer Inst 2007 Jun 20; 99(12): 936-48.
83. Fujisawa H, Kwerer M, Reis RM, Yonekawa Y, Kleihues P, Ohgaki H .Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter. Am J Pathol Aug 1999; 155: 387.
84. Ludwig RL, Bates S, Vousden KH .Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell Biol 1996; 16: 4952-4960.
85. Jensen RL .Hypoxia in the tumorigenesis of gliomas and as a potential target for therapeutic measures. Neurosurg Focus 2006 Apr 15; 20(4): E24.
86. Ichimura K, Bolin MB, Goike HM, Schmidt EE, Moshref A, Collins VP .Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res 2000; 60: 417-424.
87. Vesselska R, Kuglik P, Cejpek P, Svachova H, Neradil J, Loja T, et al.Nestin expression in the cell lines derived from glioblastoma multiforme. BMC Cancer 2006 Feb 2; 6: 32.
88. Sonoda Y, Ozawa T, Hirose Y, Aldape KD, McMahon M, Berger MS, et al.Formation of intracranial tumors by genetically modified human astrocytes defines form pathways critical in the development of human anaplastic astrocytoma. Cancer Res 2001; 61: 4956-4960.
89. Van Meir EG, Kikauchi T, Tada M, Li H, Discrens A-C, Wojcik BE, et al.Analysis of the P53 gene and its expression in human glioblastoma cells. Cancer Res Feb 1994; 54: 649-652.
90. del Arco A, Garcia J, Arribas C, Barrio R, Blazquez MG, Izquierdo J, et al.Timing of p53 mutations during astrocytoma tumorigenesis. Hum Mol Genet Oct 1993; 2: 1687-1690.
91. Bogler O, Nagane M, Gillis J, Su Huang H-J, Cavenee WK .Malignant transformation of p53-deficient astrocytes is modulated by environmental cues in vitro. Cell Growth Diff. Feb 1999; 10: 73-86.
92. Rowan S, Ludwig RL, Haupt Y, Bates S, Lu X, Oren M, et al.Specific loss of apoptotic but not cell cycle arrest function in a human tumor derived p53 mutant. EMBO J 1996; 15: 827-838.
93. Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, et al.Identification of p53 as a sequencespecific DNA-binding protein. Science (Wash DC) 1991; 252: 1708-1711.
94. Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B .Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA; 84: 6899-6903.
95. Reilly KM, Tuskan RG, Christy E, Loisil DA, Ledger J, Bronson RT, et al.Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects. PNAS Aug 2004; 101: 13008-13013.
96. Roversi G, Pfundt R, Moroni RF, Magnani I, van Reijmersdal S, Pollo B, et al.Identification of novel genomic markers related to progression to glioblastoma through genomic profiling of 25 primary glioma cell lines. Oncogene 2006 Mar 9; 25(10): 1571-83.
97. Vesselska R, Kuglik P, Cejpek P, Svachova H, Neradil J, Loja T, et al.Nestin expression in the cell lines derived from glioblastoma multiforme. BMC Cancer 2006 Feb 2; 6: 32.
98. Roversi G, Pfundt R, Moroni RF, Magnani I, van Reijmersdal S, Pollo B, et al.Identification of novel genomic markers related to progression to glioblastoma through genomic profiling of 25 primary glioma cell lines. Oncogene 2006 Mar 9; 25(10): 1571-83.
99. Rettig WJ, Chesa PG, Beresford HR, Feickert H-J, Jennings MT, Cohen J, et al.Differential expression of cell surface antigens and glial fibrillary acidic protein in human astrocytoma subsets. Cancer Res Dec 1986; 46: 6406-6412.
100. Ding H, Roncari L, Shannon P, Wu X, Lau N, Karaskova J, et al.Astrocytoma-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res 2001; 61: 3826-3836.
101. Ruiz C, Huang W, Hegi ME, Lange K, Hanou MF, Fluri E, et al.Growth promoting signaling by tenascin-C. Cancer Res 2004 Oct 15; 64(20): 7377-85.
102. Ehrmann J, Kolar Z, Mokry J .Nestin as a diagnostic and prognostic marker: immunohistochemical analysis of its expression in different tumors. J Clin Pathol 2005 Feb; 58(2): 222-3.
103. Rajasekhar VK, Viale A, Socci ND, Wiedmann M, Hu X, Holland EC .Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol Cell 2003 Oct; 12(4): 889-901.
104. Stiver SI .Angiogenesis and its role in the behavior of astrocytic brain tumors. Front Biosci 2004 Sep 1; 9: 3105-23.
105. Abdel-Fattah R, Xiao A, Bomgardner D, Peause CS, Lopes MB, Hussaini IM .Differential expression of HOX genes in neoplastic and non-neoplastic human astrocytes. J Pathol 2006 May; 209(1): 15-24.
106. Parsa AT, Holland EC .Cooperative translational control of gene expression by Ras and Akt in cancer' Trends Mol Med 2004 Dec; 10(12): 607-13.
107. Khwaja FW, Svoboda P, Reed M, Pohl J, Pyrzynska B, Van Meir EG .Proteomic identification of the wt-p53- regulated tumor cell secretome. Oncogene 2006 Dec 7; 25(58): 7650-61.
108. Xie D, Zeng YX, Wang HJ, Wen JM, Tao Y, Shain JS, et al.Expression of cytoplasmic and nuclear Survivin in primary and secondary human glioblastoma. Br J Cancer 2006 Jan 16; 94(1): 108-14.
109. Berger F, Gay E, Pelletier L, Tropel P, Wion D .Development of gliomas: potential role of asymmetrical cell division of neural stem cells. Lancet Oncol 2004 Aug; 5(8): 511-4.
110. Gil-Perotin S, Marin-Husstege M, Li J, Soriano-Navarro M, Zuidy F, Roussel MF, et al.Loss of p53 induces changes in the behavior of subventricular zone cells: implication for the genesis of glial tumors. J Neurosci 2006 Jan 25; 26(4): 1107-16.
111. Ramnaracin DB, Park S, Lee DY, Halaupaa KJ, Scoggin SO, Otu H, et al.Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. Cancer Res 2006 Jan 15; 66(2): 867-74.
112. Gil-Perotin S, Marin-Husstege M, Li J, Soriano-Navarro M, Zuidy F, Roussel MF, et al.Loss of p53 induces changes in the behavior of subventricular zone cells: implication for the genesis of glial tumors. J Neurosci 2006 Jan 25; 26(4): 1107-16.
113. McCutcheon IE, Heutschel SJ, Fuller GN, Jin W, Cote GJ .Expression of the splicing regulator polypyrimidine tract-binding protein in normal and neoplastic brain. Neuro-Oncol 2004 Jan; 6(1): 9-14.
114. Zhang Z, Zhou B, Zhang J, Chen Y, Lai T, Liang A, et al. Association of interleukin-23 receptor gene polymorphisms with risk of ovarian cancer. Cancer Genet Cytogenet 2010 Jan 15; 196(2): 146-52.
115. Massuger L, Roelofsen T, Ham MV, Butten J. The origin of serous ovarian cancer may be found in the uterus: A novel hypothesis. Med Hypotheses 2010 May; 74(5): 859-61.
116. Yamaguchi K, Mandai M, Oura T, Matsumura N, Hamaniski J, Baba T, et al. Identification of an ovarian clear cell carcinoma signature that reflects inherent disease biology and the carcinogenic processes. Oncogene 2010 2010 Mar 25; 29(12): 1741-52.
117. Stasikowska-Kanicka O, Stawerski P, Wagrowska-Danilewicz M, Danilewicz M. Immunohistochemical analysis of hMLH1 and hMSH2 proteins in serous ovarian tumors. Pol J Pathol 2009; 60(4): 174-8.
118. Laviolette LA, Garion K, Macdonald EA, Santerman MK, Courville K, Crane CA, et al. 17 Beta-Estradiol accelerates tumor onset and decreases survival in a transgenic mouse model of ovarian cancer. Endocrinology 2010 Mar; 151(3): 929-38.
119. Meimel L, Peeling L, Baozin L, Changmin L, Rujin Z, Chunjie H. Lost expression of DCC gene in ovarian cancer and its inhibition in ovarian cancer cells. Med Oncol 2011 Mar; 28(1): 282-9.
120. Kwon MJ, Kim SS, Choi YL, Jung HS, Balch C, Kim SH, et al. Derepression of CLDN3 and CLDN4 during ovarian tumorigenesis is associated with loss of repressive histone modifications. Carcinogenesis 2010 Jun; 31(6): 974-83.
121. Torng PL, Lin CW, Chan MW, Yang HW, Huang SC, Lin CT. Promoter methylation of IGFBP-3 and p53 expression in ovarian endomerioid carcinoma. Mol Cancer 2009 Dec11; 8: 120.
122. Heinrich C, Keller C, Boulay A, Vecchi M, Bianchi M, Sack R, et al. Copine III interacts with Erb-B2 and promotes tumor cell migration. Oncogene 2010 Mar 18; 29(11): 1598-610.
123. Li B, Jin H, Yu Y, Gu C, Zhou X, Zhao N, Feng Y. HOXA10 is overexpressed in human ovarian clear cell adenocarcinoma and correlates with poor survival. Int J Gynecol Cancer 2009 Nov; 19(8): 1347-52.
124. Pua TL, Wang FQ, Fishman DA. Roles of LPA in ovarian cancer development and progression. Future Oncol 2009 Dec; 5(10): 1659-73.
125. Barton CA, Gloss BS, Qu W, Statham AL, Hacker NF, Sutherland PL, et al. Collagen and calcium-binding EGF domains1 is frequently inactivated in ovarian cancer by aberrant promoter hypermethylation and modulates cell migration and survival. Br J Cancer 2010 Jan5; 102(1): 87-96.
126. Duncan TJ, Al-Attar A, Rolland P, Harper S, Spendlove I, Durrant LG. Cytoplasmic p27 expression is an independent prognostic factor in ovarian cancer. Int J Gynecol Pathol 2010 Jan; 29(1): 8-18.
127. Yang L, Xie G, Fan Q, Xie J. Activation of the hedgehog-signaling pathway in human cancer and the clinical implications. Oncogene 2010 Jan28; 29(4): 469-81.
128. Mittal S, Subramanyam D, Dey D, Kumar RV, Rangarajan A. Complications of Notch and Ras/MAPK signalling pathways in human breast carcinogenesis. Mol Cancer 2009 23; 8: 128.
129. Starlard-Davenport A, Tryndyak VP, James SR, Karf AR, Latendresse JR, Beland FA. et al. Mechanisms of epigenetic silencing of the Rassf1a gene during estrogen-induced breast carcinogenesis in AC1 rats. Carcinogenesis. 2010 Mar; 31(3): 376-81
130. Santos RA, Teisceira AC, Mayorano MB, Carrara HH, Andrade JM, Takahashi CS. Basal levels of DNA damaged detected by micronuclei and comet assaysin untreated breast cancer patients and healthy women. Clin Exp Med 2010 Jun; 10(2): 87-92.
131. Rahko E, Kauppila S, Paakko P, Blanco G, Apaja-Sarkkinen M, Talvensaari-Mattila A. et al. Immunohistochemical study of matrix metalloprotease 9 and tissue inhibitor of matrix metalloprotease 1 in benign and malignant tissue -strong expression in intraductal carcinomas of the breast. Tumor Biol 2009; 30(5-6): 257-64.
132. Raynaud CM, Hernandez J, Llorca FP, Nociforo P, Mathieu MC, Commo F. et al. DNA damage repair and telomere length in normal breast, Preneoplastic lesions and invasive cancer. Am J Clin Oncol 2010 Aug; 33(4): 341-5.
133. Hoque MO, Prencipe M, Poeta ML, Barbano R, Valori VM, Copetti M. et al. Changes in CpG islands promoter methylation patterns during ductal breast carcinoma progression. Cancer Epidemiol Biomarkers Prev 2009 Oct; 18(10): 2694-700.
134. Diehl MC, Idowu MO, Kimmelshue K, York TP, Elmore LW, Holt SE. Elevated expression of nuclear Hsp90 in invasive breast tumors. Cancer Biol Ther 2009 Oct; 8(20): 1952-61.
135. Lichtenberger BM, Tan PK, Niederleithuer H, Ferrara N, Petzelbauer P, Sibilia M. Autocrine VEGF signalling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell 2010 Jan22; 140(2): 268-279.
136. Bryant CS, Munkarah AR, Kumar S, Batchu RB, Shah JP, Berman J. et al. Reduction of hypoxia-induced angiogenesis in ovarian cancer cells by inhibition of HIF-1 alpha gene expression. Arch Gynecol Obstet 2010 Dec; 282(6): 677-83.
137. Erez N, Truitt M, Olson P, Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer cell 2010 Feb 17; 17(2): 135-47.
138. Krasnoperov V, Kumary SR, Ley E, Li X, Scehuet J, Liu R. et al. Novel EphB4 monoclonal antibodies modulate angiogenesis a nd inhibit tumor growth. Am J Pathol 2010 Apr; 176(4): 2029-38.
139. Weng L, Enomoto A, Ishida-Takagishi M, Asai N, Takahashi M. Girding for migratory cues: roles of the Akt substrate Girdin in cancer progression and angiogenesis. Cancer Sci 010 Apr; 101(4): 836-42.
140. Yeh HC, Huang CH, Yang SF, Li CC, Chang LL, Lin HH. et al. Nuclear factor-kappaB activation predicts an unfavourable outcome in human upper urinary tract urothelial carcinoma. BJU Int 2010 Oct; 106(8): 1223-9.
141. Schwartz JD, Rowinsky EK, Youssoufian H, Pytowski B, Wu Y. Vascular endothelial growth factor receptor-1 in human cancer: concise review and rationale for development of IMC-18F1 (human antibody targeting vascular endothelial growth factor receptor-1) Cancer 2010 Feb15; 116(S4): 1027-1032.
142. Cheng P, Jiang FH, Zhao LM, Dai Q, Yang WY, Zhu LM. et al. Human macrophage metalloelastase correlates with angiogenesis and prognosis of gastric carcinoma. Dig Dis Sci 2010 Nov; 55(11): 3138-46.
143. Xie TX, Xia Z, Zhang N, Gong W, Huang S. Constitutive NF-kappaB activity regulates the expression of VEGF and IL_8 and tumor angiogenesis of human glioblastoma. Oncol Rep 2010 Mar; 23(3): 725-32.
144. Tsutsui S, Matsuyama A, Yamamoto M, Takewtchi H, Oshiro Y, Ishida T. et al. The Akt expression correlates with the VEGF-A and -C expression as well as the microvessel and lymphatic density in breast cancer. Oncol Rep 2010 Mar; 23(3): 621-30.
145. Mitchell D, Pobre EG, Mulivor AW, Grinberg AV, Castonguay R, Monnell TE. et al. ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth. Mol Cancer Ther 2010 Feb; 9(2): 379-88
146. Yu L, Su B, Hollomon M, Deng Y, Facchinetti V, Kleinerman ES. Vasculogenesis driven by bone marrowderived cells is essential for growth of Ewing's sarcomas. Cancer Res 2010 Feb 15; 70(4): 1334-43.
147. Park JE, Tan HS, Datta A, Lai RC, Zhang H, Meng W. et al. Hypoxia modulates tumor microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes. Mol Cell Proteomics 2010 Jun; 9(6): 1085-99
148. Toomey DP, Manahan E, McKeown C, Rogers A, McMillian H, Geary M. et al. Vascular endothelial growth factor and not cyclooxygenase 2 promotes endothelial cell viability in the pancreatic tumor microenvironment. Pancreas 2010 Jul; 39(5): 595-603.